CreativeOne Wealth LLC Raises Stock Position in Amgen Inc. (NASDAQ:AMGN)

CreativeOne Wealth LLC lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 26.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,132 shares of the medical research company's stock after buying an additional 2,740 shares during the period. CreativeOne Wealth LLC's holdings in Amgen were worth $3,423,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Mariner LLC grew its holdings in shares of Amgen by 2.2% during the fourth quarter. Mariner LLC now owns 914,380 shares of the medical research company's stock worth $238,316,000 after purchasing an additional 19,250 shares during the last quarter. Savvy Advisors Inc. raised its stake in shares of Amgen by 5.1% during the fourth quarter. Savvy Advisors Inc. now owns 42,940 shares of the medical research company's stock valued at $11,192,000 after acquiring an additional 2,087 shares during the last quarter. Synovus Financial Corp lifted its holdings in shares of Amgen by 0.3% during the fourth quarter. Synovus Financial Corp now owns 65,729 shares of the medical research company's stock worth $17,137,000 after purchasing an additional 165 shares during the period. Summit Investment Advisors Inc. increased its holdings in Amgen by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 23,291 shares of the medical research company's stock valued at $6,071,000 after purchasing an additional 736 shares during the period. Finally, Stamos Capital Partners L.P. raised its position in Amgen by 69.5% during the 4th quarter. Stamos Capital Partners L.P. now owns 6,730 shares of the medical research company's stock worth $1,754,000 after purchasing an additional 2,760 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Jonathan P. Graham sold 25,045 shares of the business's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now owns 7,210 shares of the company's stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AMGN. UBS Group raised their price objective on Amgen from $315.00 to $319.00 and gave the stock a "neutral" rating in a research report on Monday, April 14th. Piper Sandler Companies reiterated an "overweight" rating and set a $310.00 price objective on shares of Amgen in a research report on Thursday, January 2nd. Truist Financial cut their price target on shares of Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research report on Wednesday, January 8th. StockNews.com downgraded Amgen from a "strong-buy" rating to a "buy" rating in a research note on Thursday. Finally, Bank of America lifted their target price on Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a report on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $314.91.

Amgen Stock Down 1.9 %

NASDAQ:AMGN traded down $5.35 on Friday, hitting $277.29. The stock had a trading volume of 4,371,822 shares, compared to its average volume of 2,793,769. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The firm's fifty day simple moving average is $303.04 and its two-hundred day simple moving average is $293.88. The stock has a market cap of $149.09 billion, a P/E ratio of 36.73, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.43%. Amgen's dividend payout ratio (DPR) is presently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.